Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2021 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at September Investor Conferences

SAN DIEGO and TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
August 03, 2021 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Second Quarter 2021

- Conference call and webcast at 5:00 pm EDT today - - Luxeptinib Phase 1a/b studies in AML and B cell malignancies fully enrolled at 750 mg dose - - APTO-253 Phase 1a/b study in AML / MDS treating...
July 20, 2021 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021

SAN DIEGO and TORONTO, July 20, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
June 11, 2021 07:55 ET | Source: Aptose Biosciences, Inc.

Aptose Presents Highlights from EHA During Corporate Update Event

SAN DIEGO and TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
June 01, 2021 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

SAN DIEGO and TORONTO, June 01, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
May 27, 2021 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Hold Corporate Update Friday, June 11th

Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at EHA2021 Virtual...
May 12, 2021 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at Upcoming Investor Conferences

SAN DIEGO and TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
May 04, 2021 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the First Quarter 2021

- Conference call and webcast at 4:30 pm EDT today - - Luxeptinib Phase 1 a/b studies in AML and B cell malignancies continue dose escalation - - APTO-253 Phase 1 a/b study in AML / MDS advances to...
April 26, 2021 16:02 ET | Source: Aptose Biosciences, Inc.

Aptose to Report First Quarter 2021 Financial Results and Hold Conference Call on Tuesday, May 4, 2021

SAN DIEGO and TORONTO, April 26, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the...
April 08, 2021 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference

SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...